Prostate cancer trial combines four treatments to fight recurrence
NCT ID NCT04194554
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of a targeted drug (niraparib), hormone therapy, and precise radiation for men with high-risk or node-positive prostate cancer. The goal is to find the safest dose and see if this approach improves the chance of staying cancer-free for three years. About 100 men will participate.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
niraparib (a PARP inhibitor), leuprolide (hormone blocker), abiraterone acetate (hormone blocker), and stereotactic body radiotherapy (focused radiation)
What this could lead to
If successful, this combination could offer a more effective treatment for high-risk prostate cancer, potentially delaying or preventing recurrence.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so results may not apply to all patients. The drug combination may cause serious side effects, and it's unclear if it will improve long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cornell University
New York, New York, 10065, United States
-
Mayo Clinic
Rochester, Minnesota, 55901, United States
-
University Hospitals Seidman Cancer Center
Cleveland, Ohio, 44106, United States
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
-
University of Texas Southwestern
Dallas, Texas, 75390, United States
-
Weill Cornell Medicine
New York, New York, 10065, United States